CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-01 | Li Dean Y Director | Grant or award | +2,268 | 79,618 | ||
| 2025-04-01 | Dar Zavain Director | Grant or award | +2,745 | 110,877 | ||
| 2025-03-27 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −138,574 | $6.04 | $837K | 1,117,450 |
| 2025-03-17 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −7,057 | $6.84 | $48K | 868,670 |
| 2025-03-17 | Bumpus Namandje Director | Grant or award | +36,549 | 36,549 | ||
| 2025-03-17 | Bumpus Namandje Director | Grant or award · Stock Option (Right to Buy) | +73,099 | 73,099 | ||
| 2025-03-17 | Sun Elaine D Director | Grant or award | +36,549 | 36,549 | ||
| 2025-03-17 | Sun Elaine D Director | Grant or award · Stock Option (Right to Buy) | +73,099 | 73,099 | ||
| 2025-03-06 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 1,276,024 | ||
| 2025-03-06 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $6.37 | $127K | 1,256,024 |
| 2025-03-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 5,896,700 | ||
| 2025-03-05 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 1,276,024 | ||
| 2025-03-05 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $6.58 | $132K | 1,256,024 |
| 2025-03-05 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 5,916,700 | ||
| 2025-02-18 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −17,132 | $10.64 | $182K | 1,256,024 |
| 2025-02-18 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −10,879 | $10.64 | $116K | 875,727 |
| 2025-02-06 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 1,293,156 | ||
| 2025-02-06 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $8.12 | $162K | 1,273,156 |
| 2025-02-06 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 5,936,700 | ||
| 2025-02-05 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 1,293,156 |
Page 10 of 41 · 805 trades